文献速递间质性肺疾病

双靶点抑制αvβ6与αvβ1整合素12周减少特发性肺纤维化患者I型胶原沉积:2期双盲安慰剂对照临床试验

Dual αvβ6 and αvβ1 Inhibition over 12 Weeks Reduces Active Type I Collagen Deposition in Individuals with Idiopathic Pulmonary Fibrosis: A Phase 2, Double-Blind, Placebo-controlled Clinical Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2025-01-01

这项2期单中心双盲安慰剂对照试验纳入10例特发性肺纤维化(IPF)患者,评估口服bexotegrast 160 mg治疗12周对肺内I型胶原沉积的影响。主要终点为68Ga-CBP8 PET全肺标准化摄取值变化。结果显示bexotegrast组最高四分位SUV均值变化为-1.2%,安慰剂组为6.6%,提示bexotegrast具有抗纤维化效应并可能促进有利的肺重塑。

要点

  • bexotegrast 160 mg治疗12周使IPF患者肺内68Ga-CBP8摄取降低,提示I型胶原沉积减少。
  • 胸膜下区域变化最明显:bexotegrast组-3.7%,安慰剂组10.3%。
  • FVC、咳嗽严重程度及胶原合成生物标志物呈数值改善,但样本量小。

核心结论

  • IPF患者接受bexotegrast治疗后肺内68Ga-CBP8摄取降低,提示其具有抗纤维化效应,可能促进有利的肺重塑。

研究设计与样本

  • 2期、单中心、双盲、安慰剂对照临床试验(NCT05621252)。
  • 成人IPF患者接受bexotegrast 160 mg或安慰剂治疗12周。
  • 共10例参与者,其中7例接受bexotegrast,3例接受安慰剂。
  • 主要终点为68Ga-CBP8 PET全肺标准化摄取值变化。

主要发现

  • 第12周时,68Ga-CBP8全肺标准化摄取值最高四分位的均值较基线变化:bexotegrast组-1.2%,安慰剂组6.6%。
  • 胸膜下肺区域两组均值变化最大:bexotegrast组-3.7%,安慰剂组10.3%。
  • 动态对比增强MRI显示bexotegrast组峰值强化数值增加、对比剂洗脱速率加快,提示肺微血管改善和细胞外血管外容积减少。
  • bexotegrast治疗使FVC、咳嗽严重程度及生物标志物呈数值改善。

关键数值与推荐

  • bexotegrast剂量为160 mg,每日一次口服,疗程12周。
  • 主要终点指标为68Ga-CBP8 PET全肺标准化摄取值变化。

临床怎么用

  • bexotegrast作为口服双选择性αvβ6和αvβ1整合素抑制剂,处于IPF治疗的后期评估阶段。
  • 68Ga-CBP8 PET可无创测量I型胶原沉积,或可作为评估抗纤维化疗效的影像生物标志物。

局限性

  • 样本量小(共10例,bexotegrast组7例、安慰剂组3例)。
  • 单中心研究。
  • FVC、咳嗽严重程度及生物标志物改善仅为数值变化,未报告统计学显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Idiopathic pulmonary fibrosis (IPF) is characterized by excessive deposition of type I collagen. 68Ga-CBP8, a type I collagen positron emission tomography probe, measures collagen accumulation and shows higher collagen deposition in patients with IPF. Bexotegrast (PLN-74809) is an oral, once-daily, dual-selective inhibitor of αvβ6 and αvβ1 integrins under late-stage evaluation for treatment of IPF. Objectives: To evaluate changes in type I collagen in the lungs of participants with IPF after treatment with bexotegrast. Methods: In this phase 2 (NCT05621252), single-center, double-blind, placebo-controlled study, adults with IPF received bexotegrast 160 mg or placebo for 12 weeks. The primary endpoint was the change in whole-lung standardized uptake value of 68Ga-CBP8 positron emission tomography. Changes in lung dynamic contrast-enhanced magnetic resonance imaging parameters, FVC, cough severity, and biomarkers of collagen synthesis and progressive disease were also assessed. Measurements and Main Results: Of 10 participants, 7 received bexotegrast and 3 received placebo. At Week 12, the mean change from baseline in the top quartile of 68Ga-CBP8 whole-lung standardized uptake value was -1.2% with bexotegrast versus 6.6% with placebo; the greatest mean changes were observed in subpleural lung regions in both groups (bexotegrast, -3.7%; placebo, 10.3%). Dynamic contrast-enhanced magnetic resonance imaging showed numerically increased peak enhancement and faster contrast washout rate in bexotegrast-treated participants, suggesting improvements in lung microvasculature and decreased extravascular extracellular volume. Bexotegrast treatment resulted in numerical improvements in FVC, cough severity, and biomarkers. Conclusions: The reduced uptake of 68Ga-CBP8 in the lungs of participants with IPF indicates an antifibrotic effect of bexotegrast, suggesting the potential for favorable lung remodeling. Clinical trial registered with www.clinicaltrials.gov (NCT05621252).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Montesi SB, Cosgrove GP, Turner SM, et al. Dual αvβ6 and αvβ1 Inhibition over 12 Weeks Reduces Active Type I Collagen Deposition in Individuals with Idiopathic Pulmonary Fibrosis: A Phase 2, Double-Blind, Placebo-controlled Clinical Trial. Am J Respir Crit Care Med. 2025. PMID: 40153543. doi:10.1164/rccm.202410-1934OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。